MTOR and neoplasm: According to Webber et al. [21] who based on research on molecular aberration predictive for response to everolimus, the use of mTOR inhibitor, regardless of tumor type, shows that the loss of function, aberration in Phosphatase and tensin homolog (PTEN) is associated with the success of therapy, while B-RAF wildtype could be responsible for the resistance.